<DOC>
	<DOCNO>NCT01176669</DOCNO>
	<brief_summary>The hypothesis clinical research study discover study drug apatinib shrink slow growth pretreated metastatic triple-negative breast cancer .</brief_summary>
	<brief_title>Study Apatinib Metastatic Triple-Negative Breast Cancer Patients</brief_title>
	<detailed_description>Apatinib tyrosine kinase inhibitor target vascular endothelial growth factor receptor ( VEGFR ) , anti-angiogenesis effect view preclinical test . The investigator ' phase I study show drug 's toxicity manageable maximum tolerable daily dose 850 mg . The hypothesis clinical research study discover study drug apatinib shrink slow growth triple-negative breast cancer . The safety apatinib also study . Patients physical state , symptom , change size tumor , laboratory finding obtain on-study help research team decide apatinib safe effective pretreated metastatic triple-negative breast cancer patient .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<criteria>≥ 18 ≤ 70 year age . ECOG performance status 01 . Women diagnose triple negative breast cancer ( breast cancer estrogen receptor negative ( ER ) , progesterone receptor negative ( PgR ) human epidermal growth factor receptor negative ( HER2 ) . HER2 define 0 1+ stain immunohistochemistry FISH/CISH negative gene amplification . Metastatic breast cancer , confirm histological analysis . Have fail least one chemotherapy regimen , three regimen ( include adjuvant neoadjuvant setting ) . Duration last therapy ( chemotherapy , radiotherapy , target therapy operation ) 4 week ( Duration nitroso mitomycin 6 week ) . Have least one extracranial measurable site disease accord RECIST 1.1 criterion previously irradiate . If patient previous radiation marker lesion ( ) , must evidence disease progression since radiation . Life expectancy 3 month . If patient brain meninges metastasis , lesion must control least 8 week . Adequate hepatic , renal , heart , hematologic function ( hemoglobin ≥ 9.0g/dl , neutrophil ≥ 1.5×10^9/L , platelet ≥ 80×10^9/L , ALT ≤ 2.5 x upper limit normal ( ULN ) , AST ≤ 2.5 x ULN , serum bilirubin ≤ 1.5 x ULN , serum creatine ≤ 1.5 x ULN , creatinine clearance rate ≥ 50ml/min , PT , APTT , TT , Fbg normal ) . Written inform consent prior study specific screening procedure , understand patient right withdraw study time without prejudice . Pregnant lactating woman . Less 4 week last clinical trial . Have severe and/or uncontrolled medical condition condition could affect participation study : Congestive heart failure : New York Heart Association Class III/IV , Unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction within 6 month start study drug , serious uncontrolled cardiac arrhythmia clinically significant cardiac disease . Any factor influence usage oral administration . Receiving therapy thrombolysis anticoagulation . Unhealed wound bone fracture . Urine protein ≥++ confirm ＞1.0 g 24h quantity . Previous present history pulmonary fibrosis , interstitial pneumonia , pneumoconiosis , radiation pneumonitis , drugrelated pneumonitis greatlyimpaired pulmonary function . Disability serious uncontrolled intercurrence infection . Abuse alcohol drug . Have receive prior treatment VEGFR , PDGFR sSRC TKI ( Bevacizumab permit ) . History malignancy except cure basal cell carcinoma skin carcinoma insitu uterine cervix .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Apatinib</keyword>
	<keyword>Triple-Negative Breast Cancer</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>ER/PR Negative</keyword>
	<keyword>Her2/Neu Negative</keyword>
</DOC>